SCHEMBL10133586

SCHEMBL10133586

CC1CC(C)CN(c2ccc(NC(=O)c3ccc(NS(=O)(=O)C(C)(C)C)cc3)cc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
LMNA P02545 2/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
TP53 P04637 2/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 2/20 0.46
HSD17B10 Q99714 1/20 0.46
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MCL1 Q07820 2/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ATM Q13315 1/20 0.44
PKM P14618 1/20 0.44
KDM1A O60341 4/20 0.43
MAOA P21397 4/20 0.43
MAOB P27338 4/20 0.43
KDM1B Q8NB78 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133584 1.00 MAPT (0.47) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10116218 1.00 MAPT (0.47) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10116216 1.00 MAPT (0.47) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10116192 0.88 MAPT (0.52) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10133444 0.88 MAPT (0.52) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10116222 0.88 MAPT (0.52) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10114483 0.88 MAPT (0.52) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10114504 0.84 MAPT (0.52) MAPTLMNAKMT2AMEN1TP53
SCHEMBL13204906 0.84 MAPT (0.46) MAPTLMNAKMT2AMEN1TP53
SCHEMBL10116495 0.84 MAPT (0.46) MAPTLMNAKMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
EP-2014285-A1 NPYY5 antagonists Shionogi&Co., Ltd. (JP) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3367/4885LMNA 2068/4885KMT2A 2768/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3683/4885LMNA 1857/4885KMT2A 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.